Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa In The News.
Press releases published on October 17, 2025
Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing
Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit royalties on product sales for the first license agreement …
Major Drilling Announces Normal Course Issuer Bid
MONCTON, New Brunswick, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Major Drilling Group International Inc. (“Major Drilling” or the “Company”) (TSX: MDI), the largest provider of specialized drilling services to the mining sector, announced today that the Toronto …
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
CALGARY, Alberta, Oct. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …
Emerita Extends El Cura Deposit 90 Meters Westward, Intersecting 4.1 Meters Grading 3.9% copper, 3.6% lead 8.5% Zinc, 4.08 g/t gold and 96.4 g/t silver
TORONTO, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) announces ongoing diamond drilling results that continue to intersect high grades and significantly expand the El Cura …
ITM to Announce Phase 3 COMPETE Trial Post Hoc Subgroup Analyses and Host Satellite Symposium at NANETS 2025
Garching / Munich, Germany, October 17, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that post hoc subgroup analyses data from its recent Phase 3 COMPETE trial will be presented in an oral …
Amaroq Minerals Announces Launch of Single Mine Origin Gold Sales from Nalunaq mine, Greenland
Reykjavík, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Amaroq Ltd. (“Amaroq” or the “Company”) Amaroq Minerals Announces Launch of Single Mine Origin Gold Sales from Nalunaq mine, Greenland Nalunaq gold now traceable from mine to market, available exclusively to …
Amaroq Minerals hefur sölu á gulli með SMO upprunavottun (e. Single Mine Origin – SMO)
Reykjavík, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Amaroq Minerals hefur sölu á gulli með SMO upprunavottun (e. Single Mine Origin – SMO) Amaroq Ltd. (AIM, TSX-V, NASDAQ Iceland: AMRQ, OTCQX: AMRQF) tilkynnir um upphaf á sölu SMO-vottaðs gulls úr Nalunaq-námu …
Paladin Announces Availability of Notice of Meeting for Annual General Meeting and Provides Update on Canadian Postal Service Disruption
PERTH, Australia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Paladin Energy Ltd (ASX:PDN, TSX:PDN, OTCQX:PALAF) (Paladin or the Company) advises its shareholders (Shareholders) that the Notice of Meeting and accompanying forms of proxy and voting instruction form ( …
Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering
BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that it has priced its underwritten public …
atai Life Sciences Announces Pricing of Public Offering of Common Shares
NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a …
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug …